MX2008001468A - Composiciones farmaceuticas del peptido similar al glucagon-1. - Google Patents

Composiciones farmaceuticas del peptido similar al glucagon-1.

Info

Publication number
MX2008001468A
MX2008001468A MX2008001468A MX2008001468A MX2008001468A MX 2008001468 A MX2008001468 A MX 2008001468A MX 2008001468 A MX2008001468 A MX 2008001468A MX 2008001468 A MX2008001468 A MX 2008001468A MX 2008001468 A MX2008001468 A MX 2008001468A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
glp
analogues
peptide
glucagon
Prior art date
Application number
MX2008001468A
Other languages
English (en)
Inventor
Zheng Xin Dong
Roland Cherif-Cheikh
Rigol Jose Antonio Cordero
Miravete Resureccion Alloza
Frederic Lacombe
Maestre Maria Dolores Tobalina
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of MX2008001468A publication Critical patent/MX2008001468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion esta dirigida a analogos peptidicos del peptido similar al glucagon-1, las sales farmaceuticamente aceptables de los mismos, a metodos para utilizar tales analogos para tratar a mamiferos y a composiciones farmaceuticas utiles, que comprenden por lo tanto los analogos.
MX2008001468A 2005-06-30 2006-06-30 Composiciones farmaceuticas del peptido similar al glucagon-1. MX2008001468A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69614205P 2005-06-30 2005-06-30
PCT/US2006/025826 WO2007005738A2 (en) 2005-06-30 2006-06-30 Glp-1 pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2008001468A true MX2008001468A (es) 2008-04-07

Family

ID=37605098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001468A MX2008001468A (es) 2005-06-30 2006-06-30 Composiciones farmaceuticas del peptido similar al glucagon-1.

Country Status (13)

Country Link
US (2) US8236759B2 (es)
EP (2) EP1904525A4 (es)
KR (1) KR20080028981A (es)
CN (1) CN101258163B (es)
AR (1) AR055346A1 (es)
AU (1) AU2006265814B2 (es)
CA (1) CA2617859A1 (es)
EA (1) EA012287B1 (es)
MX (1) MX2008001468A (es)
NO (1) NO20080552L (es)
NZ (1) NZ565535A (es)
TW (1) TWI364292B (es)
WO (1) WO2007005738A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523473A (ja) * 2006-12-29 2010-07-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ｇｌｐ−１医薬組成物
CA2687912C (en) * 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CA2687754C (en) * 2007-06-08 2015-12-08 Janssen Pharmaceutica N.V. Piperidine, piperazine derivatives for use as dgat inhibitors
US8633197B2 (en) * 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
UY31863A (es) 2008-06-05 2010-01-05 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EP2216042A1 (en) * 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
PL3139948T3 (pl) * 2014-05-07 2020-08-10 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591496A (en) * 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999048519A1 (en) * 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
RU2205188C2 (ru) * 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CZ295768B6 (cs) * 1998-12-07 2005-10-12 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající beta-alanin na pozici 35, jejich použití a farmaceutické prostředky je obsahující
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
WO2001051078A1 (en) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
WO2001057084A1 (en) 2000-01-31 2001-08-09 Novo Nordisk A/S Crystallisation of a glp-1 analogue
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
CN1487836A (zh) 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
MXPA02011339A (es) 2000-05-19 2003-04-25 Amylin Pharmaceuticals Inc Tratamiento del sindrome coronario agudo con glp-1.
EP1695983B1 (en) * 2000-06-16 2009-03-04 Eli Lilly & Company Glucagon-like peptide-1 analogs
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
EP1313767A2 (en) 2000-08-24 2003-05-28 Thomas Jefferson University Peptide with effects on cerebral health
NZ519752A (en) 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
EP1351984A2 (en) * 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
IL160631A0 (en) 2001-10-01 2004-07-25 Lilly Co Eli Glucagon-like peptides (glp-1) and treatment of respiratory distress
WO2003033697A1 (en) 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
CA2463803A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
JP2005518408A (ja) 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
JP2007514752A (ja) * 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
EP2409707B8 (en) * 2004-04-15 2015-05-06 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
PL1750683T3 (pl) * 2004-04-23 2013-05-31 Amgen Inc Formuły o przedłużonym uwalnianiu
CA2566873C (en) * 2004-05-20 2013-02-12 Diamedica Inc. Use of drug combinations for treating insulin resistance

Also Published As

Publication number Publication date
EA200800181A1 (ru) 2008-06-30
CN101258163B (zh) 2013-08-21
WO2007005738A3 (en) 2007-09-13
AU2006265814B2 (en) 2012-05-10
CA2617859A1 (en) 2007-01-11
NO20080552L (no) 2008-03-27
CN101258163A (zh) 2008-09-03
AU2006265814A1 (en) 2007-01-11
TWI364292B (en) 2012-05-21
EP1904525A4 (en) 2009-10-21
NZ565535A (en) 2011-03-31
TW200740456A (en) 2007-11-01
US20070021339A1 (en) 2007-01-25
US20120277151A1 (en) 2012-11-01
AR055346A1 (es) 2007-08-22
EP1904525A2 (en) 2008-04-02
EP2441460A1 (en) 2012-04-18
EA012287B1 (ru) 2009-08-28
US8236759B2 (en) 2012-08-07
WO2007005738A2 (en) 2007-01-11
KR20080028981A (ko) 2008-04-02

Similar Documents

Publication Publication Date Title
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
WO2004074315A3 (en) Analogues of glp-1
TW200740456A (en) GLP-1 pharmaceutical compositions
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
TWI262925B (en) GLP-1 analogues
DE69922043D1 (de) Glp-1 analoge
ATE522226T1 (de) Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms
EA202090392A2 (ru) Соединения-коагонисты гип и гпп-1
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
SG163517A1 (en) Antiviral compounds and methods
TW200603823A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
WO2007008684A3 (en) Ligands of melanocortin receptors
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
EP1888066A4 (en) AMINOCYCLOHEXANES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
MX2009003638A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
MX370666B (es) Novedosos moduladores del receptor de péptido tipo glucagón 1 (glp-1).
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EP2210900A3 (en) Analogues of GLP-1
TW200730190A (en) New combination to treat liver fibrosis
MX2009006942A (es) Composiciones farmaceuticas de glp-1.
MX2010001543A (es) Peptidos de surfactante pulmonar sintetico.
GB0616061D0 (en) Peptides and uses thereof
UA96003C2 (en) PHARMACEUTICAL COMPOSITION [Aib8,35]hGLP-1(7-36)NH2

Legal Events

Date Code Title Description
HC Change of company name or juridical status
GD Licence granted